The subgroups of the phase III RECOURSE trial of trifluridine/tipiracil (TAS-102) versus placebo with best supportive care in patients with metastatic colorectal cancer

201797 citationsJournal Articlehybrid Open Access

Authors

Eric Van Cutsem · Universitair Ziekenhuis Leuven

R. Mayer · Dana-Farber Cancer Institute

Stéphanie Laurent · Ghent University Hospital

Robert Winkler · Taiho Oncology (United States)

Cristina Grávalos · Hospital Universitario 12 De Octubre

Manuel Benavides · Hospital Regional Universitario de Málaga

Federico Longo-Muñoz

Abstract

Trifluridine/tipiracil was effective in all subgroups, regardless of age, geographical origin or KRAS status. This trial is registered with ClinicalTrials.gov: NCT01607957.

Topics & Keywords

Colorectal Cancer Treatments and Studies Genetic factors in colorectal cancer Hepatocellular Carcinoma Treatment and Prognosis

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: European Journal of Cancer

Volume 90, pp. 63-72

DOI: 10.1016/j.ejca.2017.10.009

Field-Weighted Citation Impact: 4.13